Murphy Canyon (MURF) to Combine with Conduit Pharmaceuticals in $700M Deal

Murphy Canyon (NASDAQ:MURF) has entered into a definitive agreement to combine with drug developer Conduit Pharmaceuticals at an enterprise value of $700.5 million. London-based Conduit is working to develop a range of treatments licensed from AstraZeneca (NASDAQ:AZN) with the aim of exiting these assets following the completion of Phase II trials. The combined company is
Read More